Compare Fiverr International Ltd (FVRR) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Philip Morris International Inc. — how do they compare? Fiverr International Ltd trades at $8.63 (market cap $310.61M), while Philip Morris International Inc. trades at $200.2 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 1006.1× Fiverr International Ltd's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Philip Morris International Inc. for 85 Days on average.
| FVRR | PM | |
|---|---|---|
Market Cap | $310.61M | $312.50B |
Volume | 381,459 | 5,517,172 |
Sector | Media | Consumer Staples |
52-Week High | $23.60 | $200.50 |
52-Week Low | $8.47 | $144.33 |
Typical Hold Time | 62 Days | 85 Days |
Enterprise Value | $63.00M | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.50, up 0.35% on the day, but has faced recent pressure with two consecutive quarterly earnings misses. The stock shows a bearish technical signal, with moving averages indicating a downtrend, while fundamentals reveal modest revenue growth to $430.91M in 2025 and a net income margin of 4.86%. Recent news highlights AI disruption compressing demand for freelance services, contributing to a 15% stock slump post-Q2 results.
The outlook remains cautious; while valuation ratios like P/E of 10.49 and P/S of 0.74 appear attractive, risks from AI competition and lowered 2026 guidance weigh on sentiment. Analyst consensus is a 'Hold' with a $10.50 price target, suggesting limited upside amid operational headwinds. Investors should balance cheap valuations against execution risks in a shifting gig economy.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
